Breaking News


Facial atopic dermatitis: A controlled trial of topical tacrolimus versus topical fluticasone


A randomized, double-blind trial of topical tacrolimus 0.1% and fluticasone 0.005% ointments evaluated their effects in 568 patients with moderate-severe facial atopic dermatitis (AD). The patients were unresponsive to or intolerant of conventional treatments for facial AD. Treatment continued for 21 days or until clearance. The primary endpoint was the 21-day response (60% or greater decrease in the modified Eczema Area and Severity Index [mEASI] score). Secondary endpoints included facial erythema and pruritus, global clinical response, treatment switching at day 21 and safety. On the primary endpoint measure, tacrolimus was superior to fluticasone (93 vs. 88%; P = 0.026). Facial erythema and pruritus improved nonsignificantly in both groups. Global clinical response (physician-assessed) ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list